Floatz logo

Dpx-Survivac

Peritoneal Cancer

ImmunoVaccine Technologies, Inc. (IMV Inc.)vaccinePhase 1/2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

37 Active assets in the Peritoneal Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Peking University
Phase 2BB
Docetaxel
University of Pittsburgh
Phase 2BB
FLUOROURACILUM
City of Hope Medical Center
Phase 3BB
Mirvetuximab Soravtansine
AbbVie
Phase 3BB
Rucaparib
pharmaand GmbH
Phase 3BB

View all 50 →

Same molecule, other indications

Dpx-Survivac is also rated in:

ovarian carcinomaDormant
B
Indicative ·
59 / 100
View asset →
relapsed/refractory diffuse large B-cell lymphomaDormant
B
Indicative ·
57 / 100
View asset →
diffuse large B-cell lymphomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →